People · Operator
Named in public records as an officer, director or promoter · active 2008–2023 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cedilla Therapeutics, Inc. | — | Biotechnology | Series C | $82.6M | $3.1B | 2020 |
| Goldfinch Bio, Inc. | — | Pharmaceuticals | Series C | $69.7M | $2.4B | 2020 |
| Taligen Therapeutics Inc | — | Biotechnology | Series B | $62.1M | $1.4B | 2008 |
| Abata Therapeutics, Inc. | — | Biotechnology | Series C | $60.3M | $168.4M | 2021 |
| PanOptica, Inc. | — | Biotechnology | Series C | $57.3M | $1.7B | 2014 |
| Rheos Medicines, Inc. | — | Biotechnology | Series B | $27.5M | $1.1B | 2018 |
ABBIE CELNIKER at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside ABBIE CELNIKER on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| NEIL EXTER | 2 | 5 |
| Shelley Chu | 1 | 10 |
| Ed Hurwitz | 1 | 9 |
| David Guyer | 1 | 8 |
| David Kaufman | 1 | 7 |
| Jake Simson | 1 | 6 |
| Lutz Giebel | 1 | 6 |
| Eli Casdin | 1 | 6 |
| Nicholas Galakatos | 1 | 6 |
| Thomas Dyrberg | 1 | 5 |
| Colin Goddard | 1 | 5 |
| Kevin Starr | 1 | 5 |
| Lorence Kim | 1 | 5 |
| Tracy Saxton | 1 | 5 |
| Bruce Peacock | 1 | 5 |
| Alexandra Glucksmann | 1 | 4 |
| Cary Pfeffer | 1 | 4 |
| Nicholas C. Galakatos | 1 | 3 |
| Timothy C Mills | 1 | 3 |
| Chris Bowden | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.